- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MERUS LABS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 18,500 | -0,27 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
18.09.2025 / 16:25 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 9,962 | 0,00 % | EyePoint Pharmaceuticals, Inc.: EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema | - DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 - - New preclinical... ► Artikel lesen | |
| AMARIN | 17,200 | +1,78 % | HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT and EPA Mechanistic Data at the Canadian Cardiovascular Congress | ||
| SELLAS LIFE SCIENCES | 1,780 | -3,16 % | SELLAS to present CDK9 inhibitor data for T-cell leukemia at ESMO | ||
| CATALYST PHARMACEUTICALS | 18,055 | +2,50 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 374,40 | -0,37 % | AKTIONÄR-Hot-Stock Madrigal: Heißer Markt - Kursziele rauf | Madrigal Pharmaceuticals hat im vergangenen Jahr Geschichte geschrieben. Mit Rezdiffra konnte das US-Unternehmen das erste Medikament überhaupt zur Behandlung der metabolischen Dysfunktion assoziierten... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 80,50 | -1,23 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting | ||
| DOGECOIN CASH | - | - | Dogecoin Cash, Inc.: Dogecoin Cash Inc. (OTCQB:DOGP) Announces Special Distribution of DogeCoin Cash (MEMECOIN:DOG) to Shareholders | MESQUITE, NV, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mesquite, NV - Dogecoin Cash Inc. (OTCQB:DOGP) today announced that its Board of Directors has approved a special distribution of DogeCoin Cash (MEMECOIN:DOG)... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| BLUM HOLDINGS | - | - | Blum Holdings Inc. Reports First Quarter 2025 Financial Results | DOWNEY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Blum Holdings, Inc. (OTCQB: BLMH) (the "Company," "Blüm," "Blüm Holdings," "we" or "us"), a California-based publicly traded holding company and cannabis... ► Artikel lesen | |
| BMP PHARMA TRADING | 4,500 | 0,00 % | PTA-News: B.M.P. Pharma Trading AG: Konzern weiterhin auf Erfolgskurs - Die Gesellschaft steigert das operative Halbjahresergebnis im Geschäftsjahr 2025 | DJ PTA-News: B.M.P. Pharma Trading AG: Konzern weiterhin auf Erfolgskurs - Die Gesellschaft steigert das operative Halbjahresergebnis im Geschäftsjahr 2025
Unternehmensmitteilung für den Kapitalmarkt... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,325 | -21,98 % | Theriva Biologics, Inc.: Theriva Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds | ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 7,390 | +6,03 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program | SYDNEY, Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,081 | +0,62 % | Allergy Therapeutics says peanut allergy vaccine trial progressing | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - 8-K, Current Report |
MERUS LABS INTERNATIONAL INC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MERUS LABS INTERNATIONAL INC finden Sie auf Wallstreet Online.